Mechanism of ITGB2 in Osteoclast Differentiation in Osteoarthritis

Abstract

Transcriptomics studies have identified integrin receptor β2 subunit (ITGB2) as a core gene in osteoarthritis (OA), strongly linked to osteoclast function in the subchondral bone. However, the mechanism through which ITGB2 regulates osteoclast function in OA remains unclear. In this study, we found that ITGB2 was negatively correlated with ITGB1 in the human subchondral bone. Proteomic analysis indicated that integrin binding is crucial in OA subchondral bone, with ITGB2 identified as a significantly upregulated protein in OA. In vitro experiments using immunoprecipitation and bimolecular fluorescence complementation revealed that ITGB2, but not ITGB1, directly interacts with Rac1 during osteoclast differentiation. Activated Rac1 promotes osteoclast differentiation and bone resorption through several mechanisms. ITGB2 knockdown reduced Rac1-GTP levels and increased ITGB1 expression. ITGB2 inhibition reduced actin ring formation and microtubule migration to the cell edge during osteoclast differentiation. Additionally, overexpression of ITGB1 in ITGB2-knockdown cells not only further suppressed ITGB2 expression but also exacerbated the inhibition of osteoclast differentiation. In a DMM mouse model, ITGB2 was associated with osteoclast activity in the subchondral bone. ITGB2 knockdown significantly reduced bone resorption and slowed OA progression by inhibiting osteoclastogenesis. In conclusion, our study identified a novel mechanism for the reciprocal regulation of integrin subunits. Moreover, inhibition of the ITGB2 signalling pathway slows subchondral bone remodelling in osteoarthritis by inhibiting osteoclast differentiation, offering a potential strategy for targeted therapeutic interventions.

Keywords

integrin / osteoarthritis / osteoclast differentiation / Rac1 / subchondral bone

References

[1] Y. Yang, Z. Lan, J. Yan, et al., “Effect of Intra-Knee Injection of Autologous Adipose Stem Cells or Mesenchymal Vascular Components on Short-Term Outcomes in Patients With Knee Osteoarthritis: An Updated Meta-Analysis of Randomized Controlled Trials,” Arthritis Research and Therapy 25 (2023): 147.

[2] W. H. Robinson, C. M. Lepus, Q. Wang, et al., “Low-Grade Inflammation as a Key Mediator of the Pathogenesis of Osteoarthritis,” Nature Reviews Rheumatology 12 (2016): 580–592.

[3] V. P. Leifer, J. N. Katz, and E. Losina, “The Burden of OA-Health Services and Economics,” Osteoarthritis and Cartilage 30 (2022): 10–16.

[4] M. Favero, E. Belluzzi, A. Ortolan, et al., “Erosive Hand Osteoarthritis: Latest Findings and Outlook,” Nature Reviews Rheumatology 18 (2022): 171–183.

[5] H. Madry, “The Subchondral Bone: A New Frontier in Articular Cartilage Repair,” Knee Surgery, Sports Traumatology, Arthroscopy 18 (2010): 417–418.

[6] L. J. Raggatt and N. C. Partridge, “Cellular and Molecular Mechanisms of Bone Remodeling,” Journal of Biological Chemistry 285 (2010): 25103–25108.

[7] A. Shibakawa, K. Yudoh, K. Masuko-Hongo, T. Kato, K. Nishioka, and H. Nakamura, “The Role of Subchondral Bone Resorption Pits in Osteoarthritis: MMP Production by Cells Derived From Bone Marrow,” Osteoarthritis and Cartilage 13 (2005): 679–687.

[8] G. Zhen and X. Cao, “Targeting TGFbeta Signaling in Subchondral Bone and Articular Cartilage Homeostasis,” Trends in Pharmacological Sciences 35 (2014): 227–236.

[9] H. Rao, G. Lu, H. Kajiya, et al., “Alpha9beta1: A Novel Osteoclast Integrin That Regulates Osteoclast Formation and Function,” Journal of Bone and Mineral Research 21 (2006): 1657–1665.

[10] H. Jin, S. Jiang, R. Wang, Y. Zhang, J. Dong, and Y. Li, “Mechanistic Insight Into the Roles of Integrins in Osteoarthritis,” Frontiers in Cell and Development Biology 9 (2021): 693484.

[11] L. Mao, L. Wang, J. Xu, and J. Zou, “The Role of Integrin Family in Bone Metabolism and Tumor Bone Metastasis,” Cell Death Discovery 9 (2023): 119.

[12] E. K. Song, J. Jeon, D. G. Jang, et al., “ITGBL1 Modulates Integrin Activity to Promote Cartilage Formation and Protect Against Arthritis,” Science Translational Medicine 10 (2018): 462.

[13] C. L. Elsegood, Y. Zhuo, G. A. Wesolowski, J. A. Hamilton, G. A. Rodan, and L. T. Duong, “M-CSF Induces the Stable Interaction of cFms With alphaVbeta3 Integrin in Osteoclasts,” International Journal of Biochemistry and Cell Biology 38 (2006): 1518–1529.

[14] A. M. El, C. Arseneault, M. Boisvert, et al., “Cooperation Between IL-7 Receptor and Integrin alpha2beta1 (CD49b) Drives Th17-Mediated Bone Loss,” Journal of Immunology 195 (2015): 4198–4209.

[15] N. A. Hotchin and A. Hall, “Regulation of the Actin Cytoskeleton, Integrins and Cell Growth by the Rho Family of Small GTPases,” Cancer Surveys 27 (1996): 311–322.

[16] S. E. LaFlamme, S. Mathew-Steiner, N. Singh, D. Colello-Borges, and B. Nieves, “Integrin and Microtubule Crosstalk in the Regulation of Cellular Processes,” Cellular and Molecular Life Sciences 75 (2018): 4177–4185.

[17] M. Zhu, B. H. Sun, K. Saar, et al., “Deletion of Rac in Mature Osteoclasts Causes Osteopetrosis, an Age-Dependent Change in Osteoclast Number, and a Reduced Number of Osteoblasts In Vivo,” Journal of Bone and Mineral Research 31 (2016): 864–873.

[18] H. Wang, T. Li, Y. Jiang, et al., “Force-Loaded Cementocytes Regulate Osteoclastogenesis via S1P/S1PR1/Rac1 Axis,” Journal of Dental Research 102 (2023): 1376–1386.

[19] B. L. Walling and M. Kim, “LFA-1 in T Cell Migration and Differentiation,” Frontiers in Immunology 9 (2018): 952.

[20] T. Hu, Z. Zhang, C. Deng, X. Ma, and X. Liu, “Effects of beta2 Integrins on Osteoclasts, Macrophages, Chondrocytes, and Synovial Fibroblasts in Osteoarthritis,” Biomolecules 12 (2022): 1653.

[21] K. Tian, X. He, X. Lin, et al., “Unveiling the Role of Sik1 in Osteoblast Differentiation: Implications for Osteoarthritis,” Molecular and Cellular Biology 44 (2024): 411–428.

[22] M. Chen, M. H. Wang, X. G. Shen, et al., “Neuropilin-1 Facilitates Pseudorabies Virus Replication and Viral Glycoprotein B Promotes Its Degradation in a Furin-Dependent Manner,” Journal of Virology 96 (2022): e131822.

[23] Y. T. Konttinen, T. F. Li, J. W. Xu, et al., “Expression of Laminins and Their Integrin Receptors in Different Conditions of Synovial Membrane and Synovial Membrane-Like Interface Tissue,” Annals of the Rheumatic Diseases 58 (1999): 683–690.

[24] J. D. Humphries, A. Byron, M. D. Bass, et al., “Proteomic Analysis of Integrin-Associated Complexes Identifies RCC2 as a Dual Regulator of Rac1 and Arf6,” Science Signaling 2 (2009): a51.

[25] B. U. Sehgal, P. J. DeBiase, S. Matzno, et al., “Integrin Beta4 Regulates Migratory Behavior of Keratinocytes by Determining Laminin-332 Organization,” Journal of Biological Chemistry 281 (2006): 35487–35498.

[26] A. M. Selim, Y. A. Elsabagh, M. M. El-Sawalhi, N. A. Ismail, and M. A. Senousy, “Association of Integrin-Beta2 Polymorphism and Expression With the Risk of Rheumatoid Arthritis and Osteoarthritis in Egyptian Patients,” BMC Medical Genomics 16 (2023): 204.

[27] W. Qian and Z. Li, “Expression and Diagnostic Significance of Integrin Beta-2 in Synovial Fluid of Patients With Osteoarthritis,” Journal of Orthopaedic Surgery 31 (2023): 773419085.

[28] B. Hopwood, A. Tsykin, D. M. Findlay, and N. L. Fazzalari, “Microarray Gene Expression Profiling of Osteoarthritic Bone Suggests Altered Bone Remodelling, WNT and Transforming Growth Factor-Beta/Bone Morphogenic Protein Signalling,” Arthritis Research and Therapy 9 (2007): R100.

[29] K. Rubio, A. J. Romero-Olmedo, P. Sarvari, et al., “Non-Canonical Integrin Signaling Activates EGFR and RAS-MAPK-ERK Signaling in Small Cell Lung Cancer,” Theranostics 13 (2023): 2384–2407.

[30] Y. K. Jung, S. W. Han, G. W. Kim, J. H. Jeong, H. J. Kim, and J. Y. Choi, “DICAM Inhibits Osteoclast Differentiation Through Attenuation of the Integrin alphaVbeta3 Pathway,” Journal of Bone and Mineral Research 27 (2012): 2024–2034.

[31] F. E. Turner, S. Broad, F. L. Khanim, et al., “Slug Regulates Integrin Expression and Cell Proliferation in Human Epidermal Keratinocytes,” Journal of Biological Chemistry 281 (2006): 21321–21331.

[32] H. Miao, S. Li, Y. L. Hu, et al., “Differential Regulation of Rho GTPases by Beta1 and Beta3 Integrins: The Role of an Extracellular Domain of Integrin in Intracellular Signaling,” Journal of Cell Science 115 (2002): 2199–2206.

[33] C. E. Turner, “Paxillin Interactions,” Journal of Cell Science 113 (2000): 4139–4140.

[34] C. Wu and S. Dedhar, “Integrin-Linked Kinase (ILK) and Its Interactors: A New Paradigm for the Coupling of Extracellular Matrix to Actin Cytoskeleton and Signaling Complexes,” Journal of Cell Biology 155 (2001): 505–510.

[35] E. Kiyokawa, Y. Hashimoto, S. Kobayashi, H. Sugimura, T. Kurata, and M. Matsuda, “Activation of Rac1 by a Crk SH3-Binding Protein, DOCK180,” Genes and Development 12 (1998): 3331–3336.

[36] S. L. Teitelbaum, “The Osteoclast and Its Unique Cytoskeleton,” Annals of the New York Academy of Sciences 1240 (2011): 14–17.

[37] S. I. Kim, Y. H. Kim, B. G. Kang, et al., “Linarin and Its Aglycone Acacetin Abrogate Actin Ring Formation and Focal Contact to Bone Matrix of Bone-Resorbing Osteoclasts Through Inhibition of Alphavbeta3 Integrin and Core-Linked CD44,” Phytomedicine 79 (2020): 153351.

[38] M. Kim, J. Lin, J. E. Huh, et al., “Tetraspanin 7 Regulates Osteoclast Function Through Association With the RANK/alphavbeta3 Integrin Complex,” Journal of Cellular Physiology 237 (2022): 846–855.

[39] K. P. McHugh, K. Hodivala-Dilke, M. H. Zheng, et al., “Mice Lacking Beta3 Integrins Are Osteosclerotic Because of Dysfunctional Osteoclasts,” Journal of Clinical Investigation 105 (2000): 433–440.

[40] E. G. Estell, P. T. Le, Y. Vegting, et al., “Irisin Directly Stimulates Osteoclastogenesis and Bone Resorption In Vitro and In Vivo,” eLife 9 (2020): 9.

[41] H. Liu, R. Zhang, S. Y. Ko, et al., “Microtubule Assembly Affects Bone Mass by Regulating Both Osteoblast and Osteoclast Functions: Stathmin Deficiency Produces an Osteopenic Phenotype in Mice,” Journal of Bone and Mineral Research 26 (2011): 2052–2067.

[42] K. J. Hamill, S. B. Hopkinson, P. DeBiase, and J. C. Jones, “BPAG1e Maintains Keratinocyte Polarity Through beta4 Integrin-Mediated Modulation of Rac1 and Cofilin Activities,” Molecular Biology of the Cell 20 (2009): 2954–2962.

[43] Q. Jian, Y. Miao, L. Tang, et al., “Rab23 Promotes Squamous Cell Carcinoma Cell Migration and Invasion via Integrin beta1/Rac1 Pathway,” Oncotarget 7 (2016): 5342–5352.

[44] O. Destaing, F. Saltel, B. Gilquin, et al., “A Novel Rho-mDia2-HDAC6 Pathway Controls Podosome Patterning Through Microtubule Acetylation in Osteoclasts,” Journal of Cell Science 118 (2005): 2901–2911.

[45] I. P. Geoghegan, D. A. Hoey, and L. M. McNamara, “Integrins in Osteocyte Biology and Mechanotransduction,” Current Osteoporosis Reports 17, no. 4 (2019): 195–206.

[46] H. Hendesi, M. F. Barbe, F. F. Safadi, M. A. Monroy, and S. N. Popoff, “Integrin Mediated Adhesion of Osteoblasts to Connective Tissue Growth Factor (CTGF/CCN2) Induces Cytoskeleton Reorganization and Cell Differentiation,” PLoS One 10 (2015): e115325.

[47] X. Lu, Y. Ito, P. Atsawasuwan, et al., “Ameloblastin Modulates Osteoclastogenesis Through the Integrin/ERK Pathway,” Bone 54 (2013): 157–168.

[48] N. K. Yee and J. A. Hamerman, “Beta(2) Integrins Inhibit TLR Responses by Regulating NF-kappaB Pathway and p38 MAPK Activation,” European Journal of Immunology 43 (2013): 779–792.

[49] G. Yang, K. Wang, H. Song, et al., “Celastrol Ameliorates Osteoarthritis via Regulating TLR2/NF-kappaB Signaling Pathway,” Frontiers in Pharmacology 13 (2022): 963506.

[50] S. S. Glasson, T. J. Blanchet, and E. A. Morris, “The Surgical Destabilization of the Medial Meniscus (DMM) Model of Osteoarthritis in the 129/SvEv Mouse,” Osteoarthritis and Cartilage 15 (2007): 1061–1069.

RIGHTS & PERMISSIONS

2025 The Author(s). Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.